Kornimate/medical-research-clean huggingface dataset:
treatment with msc in hiv-infected patients with controlled viremia and immunological discordant response

Conditions: Discordant Immunological Response in HIV Infected Subjects

Summary: phase i/iiclinical trial, proof of concept, double blind, and placebo-controlled, randomized 2:1 (mscs: placebo), total sample size is 15 subjects

this is a phase i-ii, randomised, placebo-controlled, clinical trial, currently ongoing in a single spanish hospital (hospital virgen del rocío, seville), to evaluate the safety and feasibility of a 4-doses treatment regimen with mscs (1 million cells/kg mscs, weeks 0-4-8-20) in hiv infected adults with swith discordant virological and immunological response to antiretroviral therapy. in the initial phase of the trial (n=5), patients were sequentially recruited, with a safety period of 15 days, receiving unblinded cell therapy. in the second phase of the trial, subjects are block randomised (1:1) to receive either mscs (n=5), or placebo (n=5), as the control treatment. immune response variables, adverse events, opportunistic infection signs are evaluated as determinants of safety and efficacy of mscs. study endpoints are measured along a follow-up period of 24 months, that includes 17 visits according to a decreasing frequency rate. intention to treat, and per protocol, and safety analysis will be performed.

Eligibility criteria:
inclusion criteria: * confirmed hiv infection * age\> 18 years, both sexes * in treatment with antiretroviral therapy (art) * sustained hiv viral load \<50 copies / ml for ≥ 1 years prior to study entry * cd4 + cell count \< 350/ml * immunological discordant response defined as: an increase \<75 or \<150 in cd4+ cell counts within one or two years of undetectable viraemia, respectively; or cd4 + cell count \<350/mcl after 3 years of art and undetectable viraemia (\<50 copies/ml) ≥ 1 year * writen informed consent * in women of child bearing potential or her partners:commitment to use contraceptive method of proved efficiency throughout the duration of the clinical trial exclusion criteria: * pregnancy, breastfeeding, or refusal to the use of contraceptive methods * opportunistic infections in the last 12 months prior to study entry * active co-infection with hepatitis b virus/hepatitis c virus * child pugh's scale stage c cirrhosis of the liver of any a aetiology * portal hypertension and / or hypersplenism of any aetiology * malignant neoplasia * treatment with steroids, immunomodulators, interferon, chemotherapy or any other medicinal product that could modify the number of cd4+ within the last 12 months prior to study entry * confirmed analytical 3 or 4 grade (aids clinical trials group scale) abnormalities

Keywords: mesenchymal stem cells hiv infection discordant immunological response
effects of tranexamic acid irrigation on impacted third molar surgery

Conditions: Bleeding; Tooth Extraction

Summary: tranexamic acid (txa) is an effective hemostatic agent used to reduce blood loss and the need for transfusion. it is a relatively safe drug with minimal significant side effects. the most commonly reported complications include nausea, diarrhea, and occasional orthostatic reactions. the increased risk of thromboembolic events associated with the drug is the most serious complication; however, this has not been reported in most clinical studies and remains uncertain. based on experience from other types of surgeries, tranexamic acid appears to be safe for use without an increased risk of venous thrombosis. to mitigate systemic absorption and minimize undesirable side effects, txa can be applied topically rather than intravenously, reducing the risk of venous thromboembolism.

topical txa irrigation has recently begun to be used intraoperatively. in a study conducted by eftekharian et al., the application of intraoperative 1% txa irrigation solution during bimaxillary orthognathic surgery was found to be significantly associated with a reduction in intraoperative blood loss compared to placebo. additionally, the topical application of txa to the maxillary sinus during endoscopic sinus surgery has been shown to reduce intraoperative blood loss. in the current literature, the use of tranexamic acid irrigation during tooth extraction under local anesthesia has not been reported. our study aims to demonstrate the effectiveness of txa irrigation during the extraction of bone-retained teeth and its effect on postoperative edema.

Eligibility criteria:
inclusion criteria: 1. indicated for the extraction of bilaterally impacted third molars with bone retention. 2. systemically healthy patients aged 14-40 years with no bleeding disorders. exclusion criteria: 1. patients with systemic diseases affecting general health. 2. patients diagnosed with any bleeding disorder. 3. patients with advanced infection or cysts associated with the impacted tooth.

Keywords: bleeding tranexamic acid wisdom teeth removal edema
the effact of helicobacter hylori eradication on the development of gastric mucosa pathology

Conditions: Helicobacter Gastritis

Summary: subjects who are included will recieve hp eradication therapy based on antimicrobial susceptibility test. after the therapy, the subjects will be divided into two groups, the successful group and the failure group. and then they wiil be followed up to observe the development of the gastric mucosa pathology.

subjects who are included will recieve hp eradication therapy based on antimicrobial susceptibility test. after the therapy, the subjects will be divided into two groups, the successful group and the failure group. the subjects who fail to eradicate the hp after initial treatment and rescue treatment will go into the failure group. otherwhile, they will go to the successful group.and then they wiil be followed up to observe the development of the gastric mucosa pathology. for mild atrophy gastritis, non- intestinal metaplasial gastritis, follow-up is performed every 2-3 years.for severe atrophy gastritis, intestinal metaplasial gastritis, follow-up is performed every 1-2 years. for patients wth high-grade intraepithelial neoplasia, they can be included 3 months after the endoscopic treatment, and the follow up will be performed at 6, 12 months after the treatment and then the follow up will be carried out every 1 year. for non-atrophic gastritis, no follow-up will be performed. all included patients will recieve a follow-up at the endpoint of 5 years. the follow-up includes endoscopy examination and serum test of pg i,pg ii and gastrin 17.

Eligibility criteria:
inclusion criteria: * patients, aged between 18 and 70 years old, with positive h. pylori infection that was not eradicated by previous therapies are included. the h. pylori infection is confirmed by the positive rapid urease test or 13c-breath test. exclusion criteria: * patients with significant underlying disease including liver, cardiac, pulmonary, and renal diseases, neoplasia, coagulopathy and genetic diseases, history of gastric surgery, pregnancy, breast-feeding, active gastrointestinal bleeding, patients with peptic ulcer, the use of ppi, nsaid or antibiotics during the 4 weeks prior to enrolment, and previous history of allergic reactions to any of the medications used in this protocol. patients previously treated with h. pylori eradication regimens or those unwilling to participate in the study were also excluded.
the effect of low-level laser therapy in carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome

Summary: carpal tunnel syndrome (cts) is a chronic compression of the median nerve, which can lead to symptoms such as nocturnal pain and paresthesia in the area innervated by the median nerve. the affected patients also describe discomfort and hypoesthesia in the nerve supply area. due to the covid (coronavirus disease) pandemic, cts operations have been postponed and delayed. a promising and safe alternative for improving cts-related symptoms appears to be non-invasive, non-thermal low-level-laser therapy. as a possible conservative, alternative method, low-level-laser therapy has the potential to enable patients with cts to improve their disease-related symptoms or at least to alleviate the symptoms until the indicated cts operation (carpal tunnel release). the aim of this randomized, single-blind, placebo-controlled clinical trial is to investigate the influence of 3 weeks of low-level-laser therapy on the symptoms typical of cts in patients with surgery-indicated carpal tunnel syndrome and its influence on quality of life.


Eligibility criteria:
inclusion criteria: * existing written consent of the participating person after informed consent. * the patient is capable of giving consent. * isolated surgery-induced cts * cts patients with pain (nrs between 2 and 6) and/or paresthesia and/or nocturnal pain that has been present for at least 3 months (pain reported using the "numerical rating scale for pain" (nrs) between 0 and 10). * compliance with 3 weeks of cold light therapy. exclusion criteria: * absence of informed consent * patients under 18 years or over 80 years * patients from protected groups as well as people who are not able to personally give consent * participation in other clinical trials within the last 4 weeks before the start of the study * traumatic and atraumatic median nerve lesions/damage/narrowing * previous operations in the area innervated by the median nerve or in the area of the affected upper extremity/hand * cts recurrence of the affected hand * thenar atrophy of the affected hand * nerve diseases that affect the upper extremity including the hand (e.g. polyneuropathy) * cervical radiculopathy c6/c * osteoarthritis of the affected hand (e.g. rhizarthrosis) * arthritis of the affected hand * metabolic diseases that have an influence on the sensory or function of the hand * vascular diseases affecting the upper extremity or hand (e.g. raynaud's syndrome) * other compressions or injuries of the median nerve (e.g. thoracic outlet syndrome, scalene syndrome, pronator teres syndrome)

Keywords: cts
uses of gamma irradiated amniotic membrane as an alternative method in psoriasis treatment

Conditions: Psoriasis

Summary: using of human amniotic membrane extra-cellular matrix as a topical treatment for improving psoriasis area and severity index (pasi).

human amniotic membrane extra-cellular matrix was purchased from national center for radiation research and technology, egypt, under commercial name rege pro gel.

Eligibility criteria:
inclusion criteria: * patients have psoriasis lesion exclusion criteria: * must stop other line of treatment

Keywords: amniotic membrane psoriasis treatment
cd7 car-t for patients with r/r cd7+ hematologic malignancies

Conditions: Hematological Malignancies

Summary: this is a open-label, phase 2 study to evaluate the efficacy, safety and pk of cd7 chimeric antigen receptors treatment for patients with refractory/relapsed cd7 positive hematological malignancies.


Eligibility criteria:
inclusion criteria: 1. diagnosed cd7 positive relapsed/refractory hematological malignancies. 2. echocardiography shows left ventricular ejection fraction (lvef) ≥ 50%; 3. there is no active pulmonary infection, and the oxygen saturation during air inhalation is more than 92%; 4. the estimated survival time is more than 3 months; 5. eastern cooperative oncology group (ecog) performance status of 0 to 2 6. the patients or their legal guardians voluntarily participated in the trial and signed the informed consent. exclusion criteria: 1. patients with history of epilepsy or other central nervous system diseases; 2. patients with prolonged qt or severe heart disease; 3. pregnant or lactating women 4. patients with uncontrolled active infection. 5. positive for any of the following etiological tests: hiv, hbv, hcv 6. any other conditions that researcher think it is inappropriate for the subject to anticipate the trial

Keywords: t-all/lbl aml
topical tranexamic acid (txa) in hip fractures

Conditions: Hip Fracture; Anemia

Summary: mechanisms by which to reduce exposure to allogeneic blood are of financial and clinical benefit in the hip fracture population. tranexamic acid (txa) is an inexpensive medication with low complication risk. its use in the hip fracture population is unproven. the purpose of this study is to evaluate the efficacy and safety of topical tranexamic acid in reduction of peri-operative blood loss in hip fracture surgery.

the results of this study may dramatically alter the manner in which surgeons manage hip fracture patients in canada. the use of topical txa in operatively-treated hip fracture patients has the potential to reduce perioperative blood loss and consequently reduce exposure to allogeneic blood transfusion. this will positively influence post-operative morbidity and mortality, while at the same time substantially reduce hospital length of stay and overall health care costs. the proposed study is felt to have minimal risk, and is a relatively inexpensive study. update: an interim analysis was completed in january 2018. the data safety monitoring committee reviewed the results and recommend the trial continue as planned. the final data analysis is in process. the abstract will be uploaded upon completion.

Eligibility criteria:
inclusion criteria: all of the following criteria must be met to be eligible: 1. 18 years of age or older 2. diagnosis of hip fracture (intracapsular, intratrochanteric or subtrochanteric) requiring surgical repair 3. patient/surrogate decision maker provide signed informed consent exclusion criteria: participants cannot be included in this study if any of the following criteria apply: 1. patient has documented renal failure with glomerular filtration rate of \<30ml/min/1.73m2 2. documented allergy to tranexamic acid 3. current use of hormone replacement therapy 4. acquired disturbances of colour vision 5. refusal of blood products 6. pre-operative use of anticoagulant therapy (coumadin, heparin \< 5 days of surgery, fibrinolytic disorders requiring intraoperative anti-fibrinolytic treatment) 7. coagulopathy (pre-operative platelet count \ 1.4, prolonged partial thromboplastin time (ptt) \>1.4x normal) 8. hematuria 9. acute coronary syndrome within 6 weeks of fracture 10. any history of venous thromboembolism 11. any intraoperative surgical/medical/anesthetic complications i.e.: myocardial infarction or neurovascular injury occurring prior to application of the tranexamic acid 12. pregnant or lactating 13. any major medical or psychiatric disorder that in the opinion of the investigator, might prevent the subject from completely participating in the study or interfere with the interpretation of the study results 14. unable/unwilling to provide informed consent
impact evaluation of urban water supply improvements on cholera and other diarrhoeal diseases in uvira, democratic republic of congo

Conditions: Cholera; Diarrhea

Summary: the aim of the study is to evaluate the impact of a large-scale urban water supply improvement intervention on cholera and other diarrhoeal diseases. the study uses a step wedge cluster randomised controlled trial (swcrct) to measure the effect of the intervention on cholera centre admission rates and confirmed cholera cases. a nested cohort study will examine changes in water-related practices following the intervention.


Eligibility criteria:
inclusion criteria: * uvira resident admitted to the uvira cholera treatment centre in uvira exclusion criteria: * any patients admitted during the period of intervention implementation in each cluster
safety and immunogenicity of two doses of h5n1 influenza vaccine in healthy adults

Conditions: Pandemic H5N1 Influenza

Summary: evaluate safety, tolerability and immune response of adjuvanted h5n1 cell culture derived influenza vaccine in adult subjects.


Eligibility criteria:
inclusion criteria: 1. healthy adult subjects 18 to 64 years of age, 2. individuals willing to provide written informed consent, 3. individuals in good health, 4. individuals willing to allow for their serum samples to be stored beyond the study period. exclusion criteria: 1. individuals not able to understand and follow study procedures, 2. history of any significant illness, 3. history of any chronic medical condition or progressive disease, 4. presence of medically significant cancer, 5. known or suspected impairment/alteration of immune function, 6. presence of any progressive or severe neurologic disorder, 7. presence of any bleeding disorders or conditions that prolongs bleeding time, 8. history of allergy to vaccine components, 9. receipt of any other investigational product within 30 days prior to entry into the study, 10. history of previous h5n1 vaccination, 11. receipt of any other type of seasonal vaccination within 2 months prior to entry into the study, 12. receipt of any other vaccine within 2 weeks prior to entry into the study 13. body temperature ≥38°c.0 (≥100.4° f) and/or acute illness within 3 days of intended study vaccination, 14. pregnant or breast feeding, 15. females of childbearing potential refusing to use acceptable method of birth control, 16. body mass index (bmi) ≥ 35 kg/m2, 17. history of drug or alcohol abuse, 18. any planned surgery during study period, 19. individuals conducting the study and their immediate family members, 20. individuals with behavioral or cognitive impairment or psychiatric diseases.

Keywords: influenza, pandemic, h5n1, adults
does batten grafting improve nasal outcomes in septoplasty and turbinate reduction?

Conditions: Nasal Obstruction; Septal Defect; Allergic Rhinitis; Nasal Polyps; Nasal Valve Collapse

Summary: the objective of this study is to compare the effectiveness of batten grafts plus septoplasty and turbinate reduction (intervention arm) compared to septoplasty and turbinate reduction alone (control arm), both in terms of subjective and objective assessments.

one of the most common reasons to pursue nasal surgery is for nasal obstruction caused by a septal deviation. otolaryngologists frequently perform septoplasties to improve nasal obstruction due to septal deviation, leading to improved airflow and decrease office visits and medication use. concurrently with septal deviations, the inferior turbinate tends to become hypertrophied on the contralateral side potentially causing additional nasal obstruction. while septal deviations and inferior turbinate hypertrophy are more anatomical causes of nasal obstruction, there are also other types that vary depending on nasal airflow, such as nasal valve collapse. one way to surgically correct such dynamic nasal obstruction includes alar batten grafts. these grafts are not meant to change the anatomy of the nose, but instead, function to support the weakened lateral wall. expanding the current septoplasty procedure to include batten grafts as well as inferior turbinate reduction could possibly improve long-term outcomes, especially reducing future surgeries.

Eligibility criteria:
inclusion criteria: * patients should satisfy all the following criteria to be considered eligible for randomization: 1. be age 18 or above 2. able to provide written informed consent 3. have an indication for batten graft, septoplasty and turbinate reduction according to prevailing surgical practices. 1. septal deviation must be present on direct or endoscopic examination 2. inferior turbinate hypertrophy must be present, direct examination or endoscopic examination 3. collapse of external nasal valve and/or lateral motion instability must be documented 1. the env maye be assessed clinically by observing the alar collapse at baseline or with forced inspiration, modified cottle may also be performed. in all patients, endoscopic examination should document that the (a) septal deviation, (b) turbinate hypertrophy, and (c) external nasal valve collapse are the primary contributing factors of obstructed breathing. exclusion criteria: 1. septal perforation 2. history of previous functional rhinoplasty or sinus or septal surgery 3. patients who are selected for concurrent aesthetic/cosmetic rhinoplasty 4. untreated allergic rhinitis or allergic rhinitis unresponsive to medical management 5. patients who have concurrent sinus surgery or polyp removal or concha bullosa resection
livelung - impact of cga in patients diagnosed with localized nsclc treated with sbrt

Conditions: Non-small Cell Lung Cancer; Stereotactic Body Radiotherapy; Comprehensive Geriatric Assessment

Summary: older patients with non-small cell lung cancer (nsclc) treated with stereotactic body radiation therapy (sbrt) often die from other causes than lung cancer due to age-related comorbidities. this national randomized study will include 130 patients throughout 5 danish cancer centres and investigate if a comprehensive geriatric intervention (cga) when added upfront to sbrt for patients with localized nsclc will have an impact on quality of life (qol), overall survival, physical functionality and unplanned hospital admissions. if an upfront cga improves patients' general health status, this study could lead to implementation of a cga in standard clinical practice as well as further research on older patients receiving radiotherapy.


Eligibility criteria:
inclusion criteria: * patients with cytologically or histologically proven non-small cell lung cancer * stage t1-3n0m0 * ≥ 70 years old * in a multidisciplinary setting the patient is considered medically inoperable, too frail for operation due to age and/or comorbidity or that the patient refuse surgery and therefore candidate for sbrt. exclusion criteria: * missing histology/cytology * another current malignancy * higher staging at treatment planning * not able to provide informed consent * do not speak or understand danish

Keywords: nsclc sbrt cga
continuous tart cherry juice supplementation with metabolic syndrome participants

Conditions: Metabolic Syndrome; Insulin Resistance; Hypertension

Summary: the present study examined the effect of montmorency tart cherry juice on functional and blood-based cardio-metabolic markers in humans with metabolic syndrome. participants consumed montmorency tart cherry juice or a placebo beverage continuously for 7 days in a randomised, crossover trial. outcome variables were measured immediately prior to supplementation and post-supplementation. furthermore, on the 7th day of supplementation outcome variables were measured pre- and up to 5 hours post-bolus. it was hypothesised that montmorency tart cherry juice would improve cardio-metabolic markers, particularly fasting insulin and systolic blood pressure. furthermore, the study aimed to identify the mechanism of action for any effects of montmorency tart cherry juice on blood pressure.


Eligibility criteria:
inclusion criteria: meet 3 of 5 criteria for metabolic syndrome based on national cholesterol education program-adult treatment panel iii guidelines: 1. waist circumference: \>102cm (men), \>88cm (women) 2. fasting serum triglycerides: ≥1.69 mmol.l-1 3. fasting high density lipoprotein: \<1.03 mmol.l-1 (men), \<1.29 mmol.l-1 (women) 4. blood pressure: ≥130 mmhg sbp or ≥85 mmhg dbp 5. fasting plasma glucose: ≥6.1 mmol.l-1 exclusion criteria: * smokers * current or previous history of gastrointestinal, cardiovascular, hepatic or renal disease * currently diagnosed with diabetes or uncontrolled hypertension (≥160/100 mmhg) * allergy to fructose, maltodextrin or specific fruit products * currently taking medication (such as steroids, nsaids, antibiotics, antihypertensive, hypoglycaemic, lipid-lowering drugs) * currently using any nutritional or antioxidant supplement. heavy alcohol consumption (\>14 units per week).

Keywords: montmorency tart cherry anthocyanins polyphenols metabolic syndrome insulin resistance hypertension lipid profile prediabetes